CLINICAL AND IMMUNOLOGICAL EFFICACY OF ALBENDAZOLE IN CHRONIC OPISTHORCHIASIS

It is known that deworming in chronic opisthorchiasis does not always lead to a complete clinical recovery of a person, and an imbalance in the immune system persists for a long time after getting rid of the invasion.

The objective is to evaluate the clinical and laboratory efficacy of albendazole in the treatment of opisthorchiasis invasion.

Material and methods. Taking into account the revealed changes in the immune status in chronic opisthorchiasis, a comparative assessment of the clinical and immunological efficacy of albendazole in chronic opisthorchiasis was carried out. The study involved 2 groups. The first group consisted of 30 patients receiving albendazole. The second group included 32 patients treated with praziquantel. Laboratory diagnosis of opisthorchiasis invasion was carried out using a Kato thick-smear technique with cellophane and/or biliovoscopy.

Results. The clinical effect of albendazole was a threefold decrease in frequency (20% vs. 63%, χ2 =4.2, p=0.04) and a decrease in the duration of asthenovegetative syndrome to three months (χ2=4.5, p=0.03) with a reduction in dyspeptic manifestations (13.3% vs. 37.5%, χ2 =3.9, p=0.04) – in comparison with the group of patients receiving praziquantel.

Conclusions. The clinical and immunological efficacy of albendazole in the treatment of opisthorchiasis invasion has been established: the administration of the drug leads to parasitological recovery, relief of symptoms, and normalization of immune status indicators.

1. Aftaeva L. N., Mel'nikov V. L., Nikol'skaya M. V. Opisthorchiasis in aspect of aftereffects of illness. University proceedings. Volga region. Medical sciences. 2018; 4(48):160-172. (In Russ).

2. Belov G. F., Feiginova F. A. O klinicheskoi klassifikatsii opistorkhoza (On the clinical classification of opisthorchiasis). Voprosy klinicheskoi i eksperimental'noi gastroenterologii. Novosibirsk, 1969;46:289-292. (In Russ).

3. Belozerov, E. S. (Opistorkhoz) / E. S. Belozerov, E. P. Shuvalova. – Leningrad: Meditsina, 1981. – 128 s. (In Russ).

4. Ozeretskovskaya, N. N. (Khronicheskii opistorkhoz) / N. N. Ozeretskovskaya, V. G. Bychkov, N. I. Skarednov // Meditsinskaya parazitologiya i parazitarnye bolezni. – 1985. – №5. – S. 3-11. (In Russ).

5. Pozdnyakova L.L. Opisthorchiasis in adults: clinical recommendations. [Opistorkhoz y vzroslykh: klinicheskie rekomendatsii]. Novosibirsk, 2014: 53 p. (I Russ).

6. Kuznetsova V. G., Krasnova E. I., Paturina N. G. Opisthorchiasis in the clinical practice of doctor-infectionist. Lechashhiy vrach [Attending Physician], 2013, no. 6, pp. 74. (In Russ).

7. Karbysheva N.V., Nikulina M.A., Kiushkina I.N. Opisthorchiasis invasion - a predictor of organ pathology. Zhurnal infektsionnoy patologii. 2011: 18 (3-4): 47-50. (in Russ).

8. Tumol’skaya N.I., Golovanova N.Yu., Mazmanyan M.V., Zavoykin V.D. The clinical masks of parasitic diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2014; (1): 17–27. (in Russ).

9. Wammes, L. J. Helminth therapy or elimination: epidemiological, immunological, and clinical considerations / L. J. Wammes, H. Mpairwe, A. M. Elliott, M. Yazdanbakhsh. – DOI 10.1016/S1473-3099 (14)70771-6 // Lancet Infect. Dis. – 2014. – Vol. 14, №11. – P. 1150-1162.

10. Opisthorchiasis-Induced Cholangiocarcinoma: How Innate Immunity May Cause Cancer / S.W. Edwards, E.M. Spofford, C. Price [et al.] // Adv. Parasitol. – 2018. – Vol. 101. – P. 149-176.

11. Liver Fluke-Associated Biliary Tract Cancer / P. Prueksapanich, P. Piyachaturawat, P. Aumpansub [et al.] // Gut Liver. – 2018. – Vol. 12, №3. – P. 236-245.

12. Opisthorchiasis with proinflammatory cytokines (IL-1β and TNF-α) polimorphisms influence risk of intrahepatic cholangiocarcinoma in Thailand: a nested case-control study / S. Promthet, N. Songserm, S. Woradet [et al.]. – DOI 10.1186/s12885-018-4751-5. – Text: electronic // BMC Cancer. – 2018. – Vol. 18, №1. – URL: https://doi.org/10.1186/s12885-018-4751-5 (accessed 10.03.2023).

13. Yongvanit, P. Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma / P. Yongvanit, S. Pinlaor, W. Loilome // HBPD Int. – 2014. – Vol. 21, №5. – P. 309-315.

14. Shormanov V.K., Shcherbakov D.P. Albendazole identification in terms of chemical-toxicological analysis. The Bulletin of Contemporary Clinical Medicine. 2018; 11 (3): 44-50. DOI: 10.20969/VSKM.2018.11(3).44-50.(In Russ).

15. Chai, J. Y. Albendazole and Mebendazole as Anti-Parasitic and AntiCancer Agents: an Update / J. Y.Chai, B. K. Jung, S. J. Hong. – Text: electronic // Korean J. Parasitol. – 2021. – Vol. 59, №3. – P. 189-225. – URL: https://doi.org/10.3347/kjp.2021.59.3.189 (accessed 10.03.2023).

16. Bronstein A.M., Maximova M.S., Fedyanina L.V., Burova S.V., Malyshev N.A., Lashin V.Ya., Sokolova L.V., Davidova I.V. Liver flukes: algorithm of diagnosis and treatment. Analysis of cases and review. – Epidemiologiya I infectsionnye Bolezni (Epidemiology and Infectious Diseases). - 2019. 24(1). S. 43-48. (In Russ).

17. Bakshtanovskaya I.V., Stepanova K.B., Kalgina G.A., Stepanova T.F. Relationships between biochemical parametrs in patients chronic opistorchiasis. Meditsinskaya parazitologiya i parazitarnye bolezni = Medical Parasitology and Parasitic Diseases, 2018, no. 1, pp. 13–19. (In Russ.).

18. Moskalenko O.L., Filimonova L.A., Yaskevich R.A. Changes of immunological indices in patients with chronic opisthorchiasis with the clinic of lesions of the hepatobiliary system. Siberian Journal of Life Sciences and Agriculture, 2019, vol. 11, no. 5-2, pp. 90–94. (In Russ.) doi: 10.12731/2658-6649-2019-11-5-2-90-94.